

16 February 2016

The Manager Companies
ASX Limited
20 Bridge Street
SYDNEY NSW 2000

(2 pages by email)

Dear Madam,

**BIOTRON ANTI-VIRAL COMPOUNDS TO BE TESTED IN USA
FOR ACTIVITY AGAINST ZIKA VIRUS**

Biotron Limited (ASX: BIT) ('Biotron') has contracted specialist laboratory ImQuest BioSciences based in Frederick, Maryland, USA to test the activity of specific Biotron compounds against Zika virus.

Recent international news has focused attention on a number of debilitating and life threatening viruses such as Ebola, MERS-CoV, and Zika, each of which are known to have viroporins (a group of proteins that participate in several viral functions including the promotion of release of viral particles from cells) as a part of their infection regime.

Since 2001 Biotron has been progressing the development of a unique anti-viral platform technology developing first-in-class drugs that target these viral-encoded viroporins. While Biotron's commercial focus is on the development of its anti-Hepatitis C virus (HCV) and anti-HIV-1 drug BIT225, research has been ongoing against a number of other viroporin-containing viruses.

Biotron has developed a library of viroporin-targeting compounds. Screening has shown that the library contains compounds active against HCV (all genotypes), HIV-1, Dengue, coronaviruses including SARS, Influenza A and others.

Dr Michelle Miller, Managing Director of Biotron said; "There has been increasing interest in Biotron's broad antiviral platform. This first round of screening is a starting point for Biotron's Zika program, noting that additional compounds may need to be screened, or additional chemistry undertaken to design compounds with targeted activity against this virus."

Zika virus is similar to Dengue Fever, against which Biotron has several compounds with promising antiviral activity. It is transmitted to humans primarily through the bite of certain infected mosquitoes commonly found in tropical and sub-tropical regions including north Queensland and some areas in central Queensland.

Biotron's lead drug, BIT225, has shown promising efficacy against HCV and HIV-1, and has been tested in more than 200 healthy volunteers and patients. A Phase 2 HIV-1 trial is anticipated to commence mid-2016.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn8390

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.

About ImQuest BioSciences

ImQuest BioSciences is a contract research organisation (CRO) focused on the development of agents for the prevention and treatment of infectious disease and cancer, as well as specialised capabilities to support the pre-formulation and formulation development for optimal product delivery. ImQuest's proprietary ImQuestSUCCESS platforms for virology and microbiology have assisted their clients in expediting the development of products for clinical evaluation through rapid identification of candidates with a high probability of clinical success. www.imquestbio.com.

Enquiries

Dr Michelle Miller
Managing Director
Biotron Limited
+61-2 9805 0488
+61-(0)412313329

Rudi Michelson
Monsoon Communications
+61-3 9620 3333